O-GlcNAcylation: the metabolic-immune translator in tumor evolution and treatment

Molecular Medicine · Published 2026-07-20 · DOI 10.1186/s10020-026-01573-7

Free full text

Authors (6)

Jinwen Zhao, Jincai Lv, Huanhuan Wang, Zhuangzhuang Zheng, Ying Xin, Xin Jiang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhao, J., Lv, J., Wang, H., et al. (2026). O-GlcNAcylation: the metabolic-immune translator in tumor evolution and treatment. Molecular Medicine. https://doi.org/10.1186/s10020-026-01573-7

Related articles

• Integrative machine learning and CRISPR/Cas9 analysis reveals the role of APOE in lipid metabolism–associated kidney fibrosis · Molecular Medicine · 2026 · Same journal
• ACL injury reprograms quadriceps myonuclear epigenetic and transcriptional signatures in mice · Molecular Medicine · 2026 · Same journal
• PRMT5 promotes psoriatic inflammation through mediating dimethylation of p65 in keratinocytes · Molecular Medicine · 2026 · Same journal
• Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types · Molecular Medicine · 2026 · Same journal
• From clinical suspicion to molecular detection of low-level mosaicism in NF2-related schwannomatosis via ultra-sensitive duplex sequencing · Molecular Medicine · 2026 · Same journal
• Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A · Molecular Medicine · 2026 · Same journal
• The bidirectional Thymus-Gut Axis: redefining central tolerance in digestive autoimmunity · Molecular Medicine · 2026 · Same journal
• Secretory leukocyte protease inhibitor (SLPI) attenuates TLR4/NF-κB-mediated neuroinflammation in amyotrophic lateral sclerosis: a candidate molecule associated with neuro-pathology · Molecular Medicine · 2026 · Same journal
• Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy · Molecular Medicine · 2026 · Same journal
• Bispecific antibody AP402 targets p95HER2 and induces costimulation through CD137 to improve efficacy for HER2-positive tumors · Molecular Medicine · 2026 · Same journal